



# Biotech Daily

Tuesday July 22, 2014

*Daily news on ASX-listed biotechnology companies*

- \* **ASX EVEN, BIOTECH DOWN: IMPEDIMED UP 15%, ADMEDUS DOWN 7%**
- \* **VALE AVEXA ADVISOR PROF JOEP LANGE, KILLED ON FLIGHT MH17**
- \* **OVERSUBSCRIBED ORTHOCELL IPO RAISES \$8m**
- \* **SAFETY MEDICAL PLAN UNDERWRITTEN TO \$400k FOR 3D PRINTING**
- \* **CLARIFICATION: BLUECHIIP**
- \* **FISHER FUNDS REDUCE TO 5% IN NANOSONICS**
- \* **BANK OF AMERICA, MERRILL LYNCH TAKE 8% OF SUDA**

## MARKET REPORT

The Australian stock market edged up 0.06 percent on Tuesday July 22, 2014 with the S&P ASX 200 up 3.4 points to 5,543.3 points.

Ten of the Biotech Daily Top 40 stocks were up, 14 fell, 10 traded unchanged and six were untraded.

Impedimed was the best, up 3.5 cents or 14.6 percent to 27.5 cents with 1.9 million shares traded, followed by Optiscan up 12.8 percent to 4.4 cents with 30,000 shares traded.

Starpharma climbed 4.3 percent; Anteo was up three percent; Neuren rose 2.15 percent; Living Cell, Medical Developments and Pharmaxis were up more than one percent; with Cochlear, Mesoblast, Resmed and Sirtex up less than one percent.

Admedus led the falls, down one cent or 7.4 percent to 12.5 cents with 5.1 million shares traded, followed by Patrys down 7.1 percent to 2.6 cents with 1.4 million shares traded.

Circadian lost five percent; Biotron, Oncosil and Osprey all fell 4.55 percent; Antisense, Benitec, Cellmid, Prana and Viralytics were down more than three percent; Analytica shed 2.9 percent; GI Dynamics was down 1.1 percent; with both Acrux and CSL down by 0.46 percent.

## AVEXA

Avexa says that scientific advisory board member Prof Joep Lange and his partner Jacqueline van Tongeren died on Malaysia Airlines Flight 17, en route to Melbourne. The passenger aircraft was shot down over the Eastern Ukraine.

Avexa said that Prof Lange and Ms van Tongeren were on their way to the AIDS 2014 conference in Melbourne.

The company said that Prof Lange joined the advisory board in 2006.

Avexa interim chief executive officer Dr Jonathan Coates said that Prof Lange “was a giant among HIV champions and was a great friend of Avexa, as well as the many patients for whom he cared since the HIV virus emerged in the 1980s”.

“He did great things for HIV research in many parts of the world, including in Africa,” Dr Coates said.

Avexa chairman Iain Kirkwood said the board was greatly saddened by the deaths. “Prof Lange made a great contribution to Avexa and its ATC program,” Mr Kirkwood said.

The company said that Prof Lange was a professor of medicine at the University of Amsterdam and a former president of the International AIDS Society.

Avexa said that Prof Lange was also the director of the National AIDS Therapy Evaluation Centre, senior scientific advisor of International Antiviral Therapy Evaluation Centre and chairman of Pharmaccess International Foundation, as well as a past chief of the World Health Organization's clinical research and product development branch of the Global Programme on AIDS.

Avexa was untraded at 1.3 cents.

## ORTHOCELL

Orthocell says that its oversubscribed initial public offer at 40 cents a share has raised \$8 million and the company expects to list on the ASX on August 8, 2014.

Orthocell has previously said that the funds would be primarily for the European and US regulatory processes for its autologous tenocyte implants (Ortho-ATI) and autologous chondrocyte implants (Ortho-ACI), as well as to develop its pig-based collagen scaffold for soft tissue reconstruction indications, including pelvic floor reconstruction, vaginal defects, ear drum repair and bladder wall defects (BD: May 29, Jun 5, 2014).

Today, the company said that it would have an indicative market valuation of \$33 million on being listed on the Australian Securities Exchange under the ticker code OCC.

Orthocell managing director Paul Anderson said that the response to the offer from institutional and private investors “has been fantastic”.

The company said that the offer was led by KTM Capital and Azure Capital with Shaw Stockbroking as co-manager.

## BLUECHIIP

Last night's edition reported that the Lelystad, Netherlands-based Micronic BV had moulded Bluechiip's tracking tag onto a Micronic vial.

Bluechiip chief executive officer Dr Jason Chaffey has told Biotech Daily that the tag was “not embedded into a Micronic vial, but rather a prototype vial”.

The company said that the vials would include a barcode providing two layers of identification and were undergoing low temperature testing and validation.

No sub-editors were hurt in making this clarification.

Bluechiip was untraded at five cents.

## [SAFETY MEDICAL PRODUCTS](#)

Safety Medical says its share plan at 0.2 cents a share, to fund its 3D Medical acquisition, is underwritten to \$400,000 by Street Capital Partners.

Safety Medical said that shares could be bought in parcels of \$500 to \$2,000 and the maximum of \$15,000 had been reduced to \$2,000 "to enable a greater number of eligible shareholders to participate".

The company said the share plan for holders on the record date of June 20, opened on July 21 and would close on July 31, 2014.

Last month, Safety Medical said it had a heads of agreement to acquire 3D Medical commercializing and integrating 3D printing and holographic projection technology and today said that 3D Medical had an agreement with the Melbourne-based Capitol Health to provide three-dimensional printing services for patient-specific anatomical models as visual and functional aides in diagnosis and treatment (BD: Jun 23, 2014).

Capitol Health managing director John Conidi said that three-dimensional printing was an emerging technology that would "play a fundamental part in patient diagnosis and the treatment pathway".

"In the near future 3D-printed, patient specific anatomical models will form a critical part of medical best practice protocols," Mr Conidi said. "As we have done in the past with the take up of other emerging technology, we wanted to again be at the forefront of this very exciting technology and its application in the healthcare sector."

Safety Medical said that 3D Medical expected to provide printing services to Capitol within weeks, with first revenues expected shortly after.

Safety Medical was unchanged at 0.8 cents with 77.9 million shares traded.

## [NANOSONICS](#)

Fisher Funds Management and associates have reduced their substantial shareholding in Nanosonics from 16,095,763 shares (6.16%) to 13,290,531 shares (5.03%).

The Auckland, New Zealand-based Fisher Funds said the group bought and sold shares between February 19, 2013 and July 21, 2014, with the most recent and single largest transaction the sale of 3,000,000 shares for \$2,241,000 or 74.7 cents a share.

Nanosonics was unchanged at 76.5 cents.

## [SUDA](#)

The Bank of America Corp and related bodies have increased their substantial shareholding in Suda from 62,444,080 shares (6.75%) to 77,806,856 shares (7.95%).

The Charlotte, North Carolina-based Bank of America substantial shareholder notice said that the Sydney-based Merrill Lynch (Australia) Futures and London-based Merrill Lynch International were the holders of the shares as beneficial owner and as the borrower of securities in a prime brokerage agreement, respectively.

The notice said that between March 18 and July 9, 2014 Merrill Lynch (Australia) Futures bought and sold shares, with the single largest transaction the purchase of 11,240,000 shares for \$582,000 or 5.18 cents a share, followed by Merrill Lynch International (Australia) "borrowing" 4,947,000 shares without stating any payment.

Suda fell 0.1 cents or 1.8 percent to 5.5 cents.

**Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053**  
**email: [editor@biotechdaily.com.au](mailto:editor@biotechdaily.com.au); [www.biotechdaily.com.au](http://www.biotechdaily.com.au); twitter: [@biotech\\_daily](https://twitter.com/biotech_daily)**